Abstract

People living with HIV (PLHIV) are at increased risk for cardiovascular disease (CVD), and immunity against cytomegalovirus (CMV) may be a contributing factor. We hypothesized that enhanced T-cell responses against CMV and CMV-IgG antibody-levels are associated with higher arterial blood pressure in PLHIV. We assessed serum CMV-IgG, systolic- (SBP) and diastolic- (DBP) blood pressure, pulse pressure (PP), traditional risk factors, activated CD8+ T-cells (CD38+HLA-DR+), senescent CD8+ T-cells (CD28-CD57+) and interleukin-6 (IL-6) in 60 PLHIV and 31 HIV-uninfected controls matched on age, gender, education and comorbidity. In PLHIV, expression of interleukin-2, tumor necrosis factor-α and interferon-γ was measured by intracellular-cytokine-staining after stimulation of T-cells with CMV-pp65 and CMV-gB. Associations between CMV-specific immune responses and hypertension, SBP, DBP or PP were assessed by multivariate logistic and linear regression models adjusted for appropriate confounders. The median age of PLHIV was 47 years and 90% were male. Prevalence of hypertension in PLHIV was 37% compared to 55% of HIV-uninfected controls. CMV-specific CD8+ T-cell responses were independently associated with higher PP (CMV-pp65; β = 2.29, p = 0.001, CMV-gB; β = 2.42, p = 0.001) in PLHIV. No significant differences were found with regard to individual measures of SBP and DBP. A possible weak association was found between CMV-IgG and hypertension (β = 1.33, p = 0.049) after adjustment for age, smoking and LDL-cholesterol. HIV-related factors, IL-6, CD8+ T-cell activation or CD8+ T-cell senescence did not mediate the associations, and no associations were found between CMV-specific CD4+ T-cell responses and blood pressure in PLHIV. In conclusion, increased arterial blood pressure in PLHIV may be affected by heightened CMV-specific CD8+ T-cell responses.

Highlights

  • Despite treatment with antiretroviral therapy, people living with Human immunodeficiency virus (HIV) (PLHIV) have lower life expectancy than HIV-uninfected individuals[1], partly explained by excess risk of cardiovascular diseases (CVD)[2,3,4,5]

  • A significant difference in risk of hypertension could not be identified, and no significant differences were detected in Systolic blood pressure (SBP), Diastolic blood pressure (DBP) or pulse pressure (PP) (Table 1)

  • This study identified a possible relationship between CMV-specific cellular immunity and blood pressure in people living with HIV (PLHIV) on stable treatment

Read more

Summary

Introduction

Despite treatment with antiretroviral therapy (cART), people living with HIV (PLHIV) have lower life expectancy than HIV-uninfected individuals[1], partly explained by excess risk of cardiovascular diseases (CVD)[2,3,4,5]. Hypertension is one of the major CVD risk factors[6], but studies are contradictory as to whether prevalence of hypertension is increased in treated PLHIV compared to uninfected controls [7,8,9,10]. CMV has been linked to increased risk of CVD-related morbidity and mortality in PLHIV [16], and increased magnitude of CMV-specific immune responses have been associated with subclinical cardiovascular disease[17,18,19]. The relationship between CMV and adverse CVD-outcomes is not a unique feature of HIV infection, but may be increasingly relevant in this population due to high prevalence of CMV in PLHIV, higher immune responses against CMV, and increasing life expectancy leading to a higher lifetime CMV exposure in PLHIV

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call